-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Yingpai Pharmaceutical-B (07630.HK) announced that the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) has passed a positive opinion recommending approval of the marketing license (MA) for the drug Sepalna® (Senapali). The drug is intended for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Zhitongcaijing·09/18/2026 10:57:06
Listen to the news
Zhitong Finance App News, Yingpai Pharmaceutical-B (07630.HK) announced that the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) has passed a positive opinion recommending approval of the marketing license (MA) for the drug Sepalna® (Senapali). The drug is intended for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.